Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMRHGI9)

• Drug Name: Cisplatin Drug Info
• Synonyms: Abiplatin; Biocisplatinum; Briplatin; Cismaplat; Cisplatine; Cisplatino; Cisplatinum; Cisplatyl; Citoplationo; Lederplatin; Neoplatin; Plastin; Platamine; Platidiam; Platinoxan; Randa; Cis-DDP; Cis-Diamminedichloroplatinum; Peyrone's chloride; Peyrone's salt; Cis-Dichlorodiammineplatinum(II); Cis-[PtCl2(NH3)2]; Cis-diamminedichloridoplatinum(II); Trans-diamminedichloridoplatinum(II); (SP-4-1)-diamminedichloridoplatinum; (SP-4-1)-diamminedichloroplatinum; (SP-4-2)-diamminedichloridoplatinum; (SP-4-2)-diamminedichloroplatinum; Cisplatin (Chemotherapy)
• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 5702198
  CAS Number: CAS 15663-27-1
  TTD Drug ID: D0U5HU
  VARIDT Drug ID: DR00291
  INTEDE Drug ID: DR0332
  ACDINA Drug ID: D00950

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Drug metabolism	2.28	0.00e+0	78/151 (51.66%)	ALDH3A1;CYP2C9;CYP3A4;...
Metabolism of xenobiotics by cytochrome P450	2.22	0.00e+0	49/77 (63.64%)	ALDH3A1;CYP2C9;CYP3A4;...
Complement and coagulation cascades	2.22	0.00e+0	76/85 (89.41%)	F12;SERPINA1;VWF;...
Retinol metabolism	2.20	0.00e+0	41/68 (60.29%)	ALDH1A1;CYP2C9;CYP3A4;...
Pyrimidine metabolism	1.90	3.58e-3	40/56 (71.43%)	CDA;ENTPD1;CAD;...
ECM-receptor interaction	1.89	4.47e-3	80/88 (90.91%)	COL6A2;VWF;COL4A2;...
Steroid hormone biosynthesis	1.81	1.28e-2	43/61 (70.49%)	AKR1C3;CYP3A4;UGT2B28;...
Vitamin digestion and absorption	1.80	1.23e-2	17/24 (70.83%)	SLC5A6;APOB;SLC19A1;...
Maturity onset diabetes of the young	1.79	1.39e-2	21/26 (80.77%)	FOXA2;SLC2A2;HHEX;...
Primary bile acid biosynthesis	1.75	1.79e-2	15/17 (88.24%)	BAAT;AKR1C4;ACOX2;...
Tyrosine metabolism	1.73	2.03e-2	30/36 (83.33%)	ALDH3A1;MAOA;ADH1A;...
Bile secretion	1.73	1.86e-2	68/90 (75.56%)	AQP1;ABCB4;CYP3A4;...
Caffeine metabolism	1.68	3.03e-2	5/6 (83.33%)	XDH;CYP2A6;CYP1A2
Systemic lupus erythematosus	1.66	3.32e-2	45/135 (33.33%)	HLA-DRB1;C6;C9;...
Ribosome biogenesis in eukaryotes	1.64	3.94e-2	52/108 (48.15%)	DKC1;HEATR1;EIF6;...
Notch signaling pathway	1.63	4.14e-2	49/59 (83.05%)	TLE1;NOTCH3;NCOR2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.002uM - 10uM	6H, 24H	Hide ▲

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.002uM - 10uM	6H	Hide ▲

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.002uM - 10uM	6H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.002uM - 10uM	6H, 24H	Show ▼